Vismodegib (trade name Erivedge) is a drug for the treatment of basal-cell carcinoma (BCC). The approval of vismodegib on January 30 2012 represents the first Hedgehog signaling pathway targeting agent to gain U.S. Food and Drug Administration (FDA) approval. The drug is also undergoing clinical trials for metastatic colorectal cancer small-cell lung cancer advanced stomach cancer pancreatic cancer medulloblastoma and chondrosarcoma as of June 2011.
This page contains content from the copyrighted Wikipedia article "Vismodegib"; that content is used under the GNU Free Documentation License (GFDL). You may redistribute it, verbatim or modified, providing that you comply with the terms of the GFDL.
